TN2016000014A1 - Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Info

Publication number
TN2016000014A1
TN2016000014A1 TN2016000014A TN2016000014A TN2016000014A1 TN 2016000014 A1 TN2016000014 A1 TN 2016000014A1 TN 2016000014 A TN2016000014 A TN 2016000014A TN 2016000014 A TN2016000014 A TN 2016000014A TN 2016000014 A1 TN2016000014 A1 TN 2016000014A1
Authority
TN
Tunisia
Prior art keywords
sub
preparing
pharmaceutical compositions
compositions containing
indolizine derivatives
Prior art date
Application number
TN2016000014A
Other languages
English (en)
French (fr)
Inventor
I-Jen Chen
James Edward Paul Davidson
Nanteuil Guillaume De
Olivier Geneste
Jean-Michel Henlin
Diguarher Thierry Le
Tiran Arnaud Le
James Brooke Murray
Jérôme-Benoît Starck
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2016000014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of TN2016000014A1 publication Critical patent/TN2016000014A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2016000014A 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent TN2016000014A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051885 WO2015011397A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
TN2016000014A1 true TN2016000014A1 (fr) 2017-07-05

Family

ID=50023640

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000014A TN2016000014A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Country Status (49)

Country Link
US (3) US9944620B2 (enrdf_load_stackoverflow)
EP (1) EP3024833B1 (enrdf_load_stackoverflow)
JP (1) JP6458029B2 (enrdf_load_stackoverflow)
KR (1) KR102007516B1 (enrdf_load_stackoverflow)
CN (1) CN105579450B (enrdf_load_stackoverflow)
AP (1) AP2016008990A0 (enrdf_load_stackoverflow)
AR (1) AR099913A1 (enrdf_load_stackoverflow)
AU (1) AU2014294867B2 (enrdf_load_stackoverflow)
BR (1) BR112016001328B1 (enrdf_load_stackoverflow)
CA (1) CA2918217C (enrdf_load_stackoverflow)
CL (1) CL2016000063A1 (enrdf_load_stackoverflow)
CR (1) CR20160031A (enrdf_load_stackoverflow)
CU (1) CU24380B1 (enrdf_load_stackoverflow)
CY (1) CY1119652T1 (enrdf_load_stackoverflow)
DK (1) DK3024833T3 (enrdf_load_stackoverflow)
DO (1) DOP2016000014A (enrdf_load_stackoverflow)
EA (1) EA030323B1 (enrdf_load_stackoverflow)
ES (1) ES2650814T3 (enrdf_load_stackoverflow)
FR (1) FR3008976A1 (enrdf_load_stackoverflow)
GT (1) GT201600017A (enrdf_load_stackoverflow)
HK (1) HK1222394A1 (enrdf_load_stackoverflow)
HR (1) HRP20171752T1 (enrdf_load_stackoverflow)
HU (1) HUE037498T4 (enrdf_load_stackoverflow)
IL (1) IL243742B (enrdf_load_stackoverflow)
JO (1) JO3310B1 (enrdf_load_stackoverflow)
LT (1) LT3024833T (enrdf_load_stackoverflow)
MA (1) MA38803A1 (enrdf_load_stackoverflow)
MD (1) MD4643C1 (enrdf_load_stackoverflow)
ME (1) ME02922B (enrdf_load_stackoverflow)
MX (1) MX365916B (enrdf_load_stackoverflow)
MY (1) MY178251A (enrdf_load_stackoverflow)
NI (1) NI201600015A (enrdf_load_stackoverflow)
NO (1) NO3024833T3 (enrdf_load_stackoverflow)
NZ (1) NZ716156A (enrdf_load_stackoverflow)
PE (1) PE20160240A1 (enrdf_load_stackoverflow)
PH (1) PH12016500057B1 (enrdf_load_stackoverflow)
PL (1) PL3024833T3 (enrdf_load_stackoverflow)
PT (1) PT3024833T (enrdf_load_stackoverflow)
RS (1) RS56451B1 (enrdf_load_stackoverflow)
RU (1) RU2693629C2 (enrdf_load_stackoverflow)
SA (1) SA516370448B1 (enrdf_load_stackoverflow)
SG (2) SG10201800580XA (enrdf_load_stackoverflow)
SI (1) SI3024833T1 (enrdf_load_stackoverflow)
TN (1) TN2016000014A1 (enrdf_load_stackoverflow)
TW (1) TWI511969B (enrdf_load_stackoverflow)
UA (1) UA119243C2 (enrdf_load_stackoverflow)
UY (1) UY35626A (enrdf_load_stackoverflow)
WO (1) WO2015011397A1 (enrdf_load_stackoverflow)
ZA (1) ZA201600350B (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
TWI759316B (zh) 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
PL3697785T3 (pl) 2017-10-18 2023-08-07 Jubilant Epipad LLC Związki imidazopirydynowe jako inhibitory pad
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2019087214A1 (en) 2017-11-06 2019-05-09 Jubilant Biosys Limited Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
AU2018372211B2 (en) 2017-11-24 2023-02-02 Jubilant Episcribe LLC, Heterocyclic compounds as PRMT5 inhibitors
CA3093527A1 (en) 2018-03-13 2019-09-19 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2020231723A1 (en) * 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
UY39670A (es) 2021-03-12 2022-07-29 Eil Therapeutics Inc Compuestos que tienen tetrahidroindolizina-1-carboxamida como inhibidores de bcl-2
CR20240553A (es) 2022-05-20 2025-05-02 Servier Lab Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230890D1 (de) * 2001-09-19 2009-03-05 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用
CA2577752A1 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
BRPI0620151A2 (pt) 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
CN101743224A (zh) 2007-04-16 2010-06-16 雅培制药有限公司 7-取代的吲哚mcl-1抑制剂
EP2149560B1 (en) 2007-05-22 2015-05-13 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
WO2009073545A2 (en) 2007-11-30 2009-06-11 Maxthera, Inc. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
EP2252617A1 (en) 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
PL2252317T3 (pl) 2008-02-15 2014-09-30 Univ Tufts Leczenie zwyrodnienia plamki żółtej
CN103732589B (zh) * 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
US20140357666A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
DK2609926T3 (da) 2011-12-30 2014-01-06 Jakob Hraschan Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EA201600124A1 (ru) 2016-07-29
AP2016008990A0 (en) 2016-01-31
IL243742A0 (en) 2016-04-21
NO3024833T3 (enrdf_load_stackoverflow) 2018-02-03
PH12016500057A1 (en) 2016-03-28
US9944620B2 (en) 2018-04-17
HRP20171752T1 (hr) 2017-12-29
MY178251A (en) 2020-10-07
DK3024833T3 (en) 2017-12-18
GT201600017A (es) 2018-10-08
RU2016105999A (ru) 2017-08-28
CA2918217C (fr) 2018-06-12
TWI511969B (zh) 2015-12-11
MX2016000906A (es) 2016-05-05
US10414754B2 (en) 2019-09-17
MD4643B1 (ro) 2019-08-31
KR102007516B1 (ko) 2019-08-05
HK1222394A1 (zh) 2017-06-30
HUE037498T4 (hu) 2018-11-28
BR112016001328B1 (pt) 2022-03-03
CA2918217A1 (fr) 2015-01-29
AU2014294867B2 (en) 2018-10-04
AR099913A1 (es) 2016-08-31
AU2014294867A1 (en) 2016-02-11
EP3024833B1 (fr) 2017-09-06
LT3024833T (lt) 2017-10-25
WO2015011397A1 (fr) 2015-01-29
US20180186771A1 (en) 2018-07-05
EA030323B1 (ru) 2018-07-31
HUE037498T2 (hu) 2018-08-28
CU24380B1 (es) 2019-02-04
CR20160031A (es) 2016-04-04
MA38803A1 (fr) 2017-10-31
DOP2016000014A (es) 2016-03-15
PL3024833T3 (pl) 2018-02-28
RS56451B1 (sr) 2018-01-31
NI201600015A (es) 2016-02-11
ES2650814T3 (es) 2018-01-22
CN105579450B (zh) 2017-12-12
BR112016001328A2 (enrdf_load_stackoverflow) 2017-07-25
ZA201600350B (en) 2017-05-31
JP6458029B2 (ja) 2019-01-23
CU20160011A7 (es) 2016-05-30
PE20160240A1 (es) 2016-04-30
CY1119652T1 (el) 2018-04-04
IL243742B (en) 2019-06-30
PT3024833T (pt) 2017-10-06
US20160176848A1 (en) 2016-06-23
JO3310B1 (ar) 2018-09-16
MD20160016A2 (ro) 2016-07-31
UA119243C2 (uk) 2019-05-27
FR3008976A1 (fr) 2015-01-30
KR20160034387A (ko) 2016-03-29
JP2016525536A (ja) 2016-08-25
MX365916B (es) 2019-06-20
NZ716156A (en) 2019-05-31
PH12016500057B1 (en) 2016-03-28
HK1223360A1 (zh) 2017-07-28
SG11201600318RA (en) 2016-02-26
CN105579450A (zh) 2016-05-11
RU2693629C2 (ru) 2019-07-03
EP3024833A1 (fr) 2016-06-01
UY35626A (es) 2015-02-27
US20190359595A1 (en) 2019-11-28
SG10201800580XA (en) 2018-03-28
MD4643C1 (ro) 2020-03-31
TW201504238A (zh) 2015-02-01
ME02922B (me) 2018-04-20
SA516370448B1 (ar) 2018-12-12
SI3024833T1 (sl) 2017-12-29
RU2016105999A3 (enrdf_load_stackoverflow) 2018-04-28
CL2016000063A1 (es) 2016-08-19

Similar Documents

Publication Publication Date Title
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37213B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
FR3041640B1 (fr) NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
MA38404A1 (fr) Nouveaux dérivés de pyridine
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MA50450B1 (fr) Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
MA33641B1 (fr) Nouveaux derives dihydro-oxazolobenzodiazepinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent